WO2005001093A1 - 細胞外基質沈着タンパク質 - Google Patents
細胞外基質沈着タンパク質 Download PDFInfo
- Publication number
- WO2005001093A1 WO2005001093A1 PCT/JP2004/009616 JP2004009616W WO2005001093A1 WO 2005001093 A1 WO2005001093 A1 WO 2005001093A1 JP 2004009616 W JP2004009616 W JP 2004009616W WO 2005001093 A1 WO2005001093 A1 WO 2005001093A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- seq
- amino acid
- extracellular matrix
- acid sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 148
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 105
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 105
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 101
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 94
- 230000008021 deposition Effects 0.000 title claims abstract description 74
- 239000012634 fragment Substances 0.000 claims abstract description 119
- 230000036961 partial effect Effects 0.000 claims abstract description 104
- 230000000694 effects Effects 0.000 claims abstract description 96
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 76
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 claims abstract description 73
- 150000001413 amino acids Chemical class 0.000 claims abstract description 34
- 238000000151 deposition Methods 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 57
- 239000002773 nucleotide Substances 0.000 claims description 39
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 230000001105 regulatory effect Effects 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000012377 drug delivery Methods 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000005137 deposition process Methods 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 65
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 46
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 37
- 210000004185 liver Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 210000005228 liver tissue Anatomy 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000002464 Galactosidases Human genes 0.000 description 5
- 108010093031 Galactosidases Proteins 0.000 description 5
- 101150030759 del-1 gene Proteins 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000002306 biochemical method Methods 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 4
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101800002899 Soluble alkaline phosphatase Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010049959 Discoidins Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001211763 Yukara Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- -1 isotopes Proteins 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 102000050137 human EDIL3 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
Definitions
- the present invention relates to extracellular matrix deposition proteins that are partial fragments of the endothelial cell locus-l (Del-l) protein. Further, the present invention relates to a method for identifying an extracellular matrix deposition site using the above partial fragment, and a method for recovering a target molecule (eg, alkaline phosphatase) fused to a Del-1 protein.
- a target molecule eg, alkaline phosphatase
- Del-l developmentally endothelial locus-1 protein
- EGF epidermal growth factor
- discoidin I-like domain Protein.
- This protein is an extracellular matrix protein that binds to a protein called ⁇ / 33 integrin receptor or] 35 integrin receptor on the surface of vascular endothelial cells via an EGF-like domain, and binds to endothelial cells. It is known to promote adhesion to the outer matrix (Hidai, C. et al., GENES & DEVELOPMENT 12: 21-33, 1998).
- full-length Del-1 In recent years, the gene encoding full-length Del-l has been cloned. It has been speculated that full-length Del-1 can bind to proteodalican in the extracellular matrix through part or all of it. Therefore, full-length Del-1 is expressed and a predetermined molecule (protein, proteodalican, etc.) is bound to full-length Del-1, and a molecule bound to full-length Del-1 (protein, proteodarican, etc.) is recovered. A known method is known (see, for example, Japanese Patent Publication No. 11-507527).
- identifying these binding sites and analyzing the binding mode is important for recovery of the target molecule and for research and analysis of the molecule binding to full-length Del-1.
- An object of the present invention is to provide a partial fragment of Del-1 containing a region that can efficiently adhere to an extracellular matrix.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that a region near the discoidin I-like domain is efficiently deposited on the extracellular matrix, and have completed the present invention.
- Ob consists of the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12, 18 or 24 in which one or several amino acids are deleted, substituted or added, and is extracellular Proteins with deposition activity on substrates
- a method for producing a partial Del-l fragment comprising culturing the transformant according to (11) and collecting a partial fragment of the Del-l protein from the resulting culture.
- a reagent for identifying an extracellular matrix deposition site comprising the protein according to any one of (1) to (3).
- a fusion protein wherein the protein according to any one of (1) to (3) is linked to a target molecule for expression.
- a gene encoding a fusion protein wherein the gene according to any one of (4) to (9) is linked to a gene encoding a target molecule for expression.
- a method for producing the fusion protein comprising culturing the transformant according to (19), and collecting a fusion protein of a partial fragment of Del-1 protein and a target molecule for expression from the resulting culture.
- (21) A method for recovering a target molecule, comprising depositing the fusion protein according to (15) on an extracellular matrix and collecting the target molecule.
- the method comprising: (23) A method for recovering a target molecule, comprising the following steps:
- the method comprising:
- a Del-1 partial fragment is provided. Since the expressed protein of the Del-l partial fragment has an activity of depositing on the extracellular matrix, the use of the Del-l partial fragment allows the target molecule bound to the expressed protein of the Del-l partial fragment to be efficiently converted to the extracellular matrix. Can be deposited. Further, the target molecule can be recovered or removed by the deposition.
- the target molecule By depositing the target molecule on the extracellular matrix using the Del-1 partial fragment, the target molecule can be concentrated and localized in the target tissue. In particular, the transfer of the target molecule to plasma can be prevented by preventing the molecule from flowing out to plasma.
- the Del-1 partial fragment of the present invention also includes a fragment that expresses a protein having a function of suppressing deposition on an extracellular matrix. Therefore, by increasing or decreasing the deposition activity by combining a fragment having a deposition activity with a fragment that inhibits deposition on the extracellular matrix, Controlling recovery, removal, concentration, etc. of target molecules Brief description of drawings
- FIG. 1 is a diagram showing the outline of the nucleotide sequence of the Del-1 partial fragment of the present invention and the results of measuring the deposition activity of each partial fragment by alkaline phosphatase activity.
- FIG. 2 is a diagram showing the binding activity of the Del-1 partial fragment of the present invention to an extracellular matrix.
- FIG. 3 is a diagram showing the AP / Lac ratio in plasma collected from each liver.
- FIG. 4 is a diagram showing the AP / Lac ratio in liver tissue collected from each liver.
- FIG. 5 is a diagram showing the results of staining of liver tissue collected from each liver with alkaline phosphatase.
- FIG. 6 is a diagram showing a Western plot.
- FIG. 7 is a diagram showing the results of the recovery of Ari-Liphospha. BEST MODE FOR CARRYING OUT THE INVENTION
- the present invention relates to partial fragments of the full-length Del-1 protein including a region that specifically binds to the extracellular matrix, that is, a Del-1 deposition protein and a Del-1 deposition inhibitory protein (also simply referred to as “Del_l partial fragment”). It is about.
- the Del-1 partial fragment of the present invention is produced by cutting full-length Del-1 to various lengths, and has a characteristic of having an activity of depositing on an extracellular matrix.
- the Del-1 partial fragment of the present invention comprises at least an amino acid encoded by a region of the nucleotide sequence of 1270 to 1662 of the full-length Del-1 gene (SEQ ID NO: 1) (amino acid represented by SEQ ID NO: 2). Amino acid sequence at positions 218 to 348 of the sequence).
- SEQ ID NO: 1 amino acid represented by SEQ ID NO: 2
- Amino acid sequence at positions 218 to 348 of the sequence The nucleotide sequence of this region is shown in SEQ ID NO: 3, and the amino acid sequence encoded thereby is shown in SEQ ID NO: 4.
- Del-1 partial fragment of the present invention containing the above-mentioned region has the nucleotide sequence shown in SEQ ID NO: 5, 7, 9, 11, 13, 15 or 17, and according to these nucleotide sequences, The encoded amino acid sequences are shown in SEQ ID NOs: 6, 8, 10, 12, 14, 16, 16 or 18, respectively.
- the partial fragment of Del-1 is derived from the amino acid sequence It is speculated that it can be combined with.
- a detection method using an alkaline phosphatase is employed. That is, by expressing a protein in which alkaline phosphatase is fused to the N-terminus of the full-length Del-l protein by genetic recombination in cells, the alkaline phosphatase activity can be confirmed in the culture supernatant as well as the extracellular matrix. Can be.
- a Western plot method can also be used for detection of the Del-1 partial fragment and the like.
- a nucleotide sequence encoding an amino acid protein obtained by fusing the enzyme phospholipase with full-length Del-l or a partial fragment of Del-l is introduced into cos7 cells, and after culturing for a certain time, And extracellular matrix can be collected and detected by Western blot.
- laminin and albumin can be used as the control unit.
- the amount of the culture solution used may be increased and the protein may be concentrated.
- a Del-l partial fragment of the present invention obtained by cleaving a known full-length Del-l by various methods is prepared, and the Del-l partial fragment is converted into an alkaline phosphatase.
- Extracellular matrix deposition ability was examined by the above-mentioned detection method and Western blotting method used.
- the deposition site of the Del-1 partial fragment on the extracellular matrix was identified, and the Del-1 partial fragment was fixed to a specific site in vivo.
- the expression product of the target gene was recovered using the Del-1 partial fragment.
- the Del-l partial fragment can be obtained by cutting the DNA encoding full-length Del-l into various lengths and expressing it. Cloning of the full-length Del-1 gene can be performed according to a known method (Hidai C. et al., GENES & DEVELOPMENT, 12: 21-33, 1998). In other words, exons can be obtained from a genome library by exon trapping and used to clone cDNA.
- a fragment of a genomic clone is inserted into a splicing vector to cause splicing during transcription of mRNA.
- the spliced mRNA is reverse transcribed and amplified, and exon sequencing is performed.
- the obtained exon is used as a probe for picking up target DNA from a cDNA library or used for designing a gene-specific primer for 5'-RACE and 3'-RACE.
- a commercially available kit for example, Marathon TM cDNA Amplification Kit> Clontech can be used to perform the RACE method.
- the nucleotide sequence of the cDNA can be determined by any known technique, but usually the sequence is determined using an automatic nucleotide sequencer.
- the nucleotide sequence of the full-length cDNA thus obtained is shown in SEQ ID NO: 1.
- the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 1 is shown in SEQ ID NO: 2.
- One of the truncated Del-1 partial fragments of the present invention comprises the amino acid sequence of positions 1 to 348 of the amino acid sequence shown in SEQ ID NO: 2.
- the partial fragment can be obtained by sequentially removing DNA having the nucleotide sequence shown in SEQ ID NO: 1 from the 3 'end using Exonuclease III and Mung bean nuclease.
- the DNA at the 3 'end to be deleted is determined by the reaction time of Exonuclease III.
- a commercially available enzyme for example, Exonuclease III: manufactured by Yukara Bio Inc.
- a schematic diagram of the full-length Del-l (Del-l major), the truncated Del_l partial fragment of the present invention, and the amino acid sequence that affects the deposition activity of the partial fragment is shown in the upper left part of FIG.
- CY is 218 to 348 (SEQ ID NO: 4)
- 4-1 is 1 to 348 (SEQ ID NO: 6)
- 4-14 is 1 to 368 (sequence) in the amino acid sequence shown in SEQ ID NO: 2.
- Nos. 10) and 4-13 have amino acid sequences of regions 1 to 385 (SEQ ID NO: 12)
- CB has regions 218 to 480 (SEQ ID NO: 14)
- XY has regions of 123 to 348 (SEQ ID NO: 18).
- DNAs encoding these Del-1 partial fragments are CY
- SEQ ID NO: 1 From 1270 to 1662 (393 bp, SEQ ID NO: 3), for 4-1 to 619 to 1662 (1044 bp, SEQ ID NO: 5), for 4-14 to 619 to 1722 (1104 bp, SEQ ID NO: 9), 619 to 4-13: L773 (1155 bp, SEQ ID NO: 11), CB: 1270 to 2058 (789 bp, SEQ ID NO: 13), XY: 985 to 1662 (678 bp, 678 bp, It has the nucleotide sequence of the region of SEQ ID NO: 17).
- human XY (SEQ ID NO: 24) corresponding to the mouse fragment XY (SEQ ID NO: 18) was also measured for full-length human Del-1.
- DNA encoding human XY has the nucleotide sequence of SEQ ID NO: 23.
- 4-15 are amino acids 1-365 (SEQ ID NO: 8) of the amino acid sequence shown in SEQ ID NO: 2, and DE is 218- It has the amino acid sequence of the region of No. 319 (SEQ ID NO: 16).
- the DNAs encoding these amino acid sequences include the nucleotides 619 to 1713 (1095 bp, SEQ ID NO: 7) of the nucleotide sequence shown in SEQ ID NO: 1 for 4-15, and the DNAs of 1270 to 1575 (306 bp, SEQ ID NO: 15) for DE. It has the amino acid sequence of the region.
- XC is 123 to 217 (SEQ ID NO: 20)
- YB is 349 to 480 (SEQ ID NO: 22). Region.
- the DNAs encoding these amino acid sequences have the nucleotide sequences of 985 to 1269 (285 bp, SEQ ID NO: 19) for XC and 1663 to 2058 (396 bp, SEQ ID NO: 21) for YB.
- the partial fragment of the present invention contains at least CY represented by the amino acid sequence of positions 218 to 348 (SEQ ID NO: 4) of the amino acid sequence represented by SEQ ID NO: 2.
- the partial fragment of the present invention includes a protein in which a plurality of amino acid sequences of at least 218 to 348 (SEQ ID NO: 4) of the amino acid sequence shown in SEQ ID NO: 2 are linked. These regions are central regions that have deposition activity on the extracellular matrix.
- the above-mentioned CY is encoded by the region of Nos. 1270 to 1662 of the nucleotide sequence shown in SEQ ID NO: 1 (SEQ ID NO: 3).
- the amino acid sequence (XC) shown in SEQ ID NO: 20 improves the deposition activity on extracellular matrix, and is a positive regulatory region for the deposition activity.
- the amino acid sequence (YB) shown in SEQ ID NO: 22 reduces the deposition activity on extracellular matrix. It is a negative regulatory region of the deposition activity.
- “Positive regulatory region” means a region that does not produce deposition activity by itself but can induce deposition activity by including the central region CY.
- Negative regulatory region means a region of a fragment in which the deposition activity is reduced and the soluble fraction is increased due to the presence or absence of the central region CY or the positive regulatory region XC due to the presence of all or a part thereof. I do.
- Table 1 summarizes the regions of the Del-1 partial fragment (derived from mouse and human) of the present invention.
- the region is indicated by base number for DNA and amino acid number for protein.
- At least one, preferably one or several amino acids in the amino acid sequence of the Del-l partial fragment are used as long as the protein has an activity of depositing with an extracellular matrix. Mutations such as deletion, substitution, and addition may occur in amino acids.
- the gene of the present invention includes a gene encoding a protein containing the amino acid sequence into which the mutation has been introduced, as long as the protein has an activity of depositing on an extracellular matrix.
- At least one, preferably one or several amino acids in the amino acid sequence of the Del-l partial fragment are used as long as the protein has a function of suppressing deposition on the extracellular matrix. Mutations such as deletion, substitution, and addition may occur in the amino acids.
- one or several, for example, 1 to 10, preferably 1 to 5 amino acids of the amino acid sequence shown in SEQ ID NO: 14 which is a CB region may be deleted, and the amino acid sequence shown in SEQ ID NO: 14 L0, preferably 1 to 5 amino acids may be added to the amino acid sequence, or 1 or several amino acids of the amino acid sequence shown in SEQ ID NO: 14, for example 1 to 10 , Preferably 1 to 5 amino acids may be substituted for other amino acids. It is included in the gene of the present invention as long as it has an activity of suppressing the deposition of chromium.
- the deletion, substitution, introduction of mutation such as addition, the mutagenesis kit utilizing site-directed mutagenesis, e.g.
- a DNA consisting of a nucleotide sequence complementary to a DNA encoding the above-mentioned Del-I partial fragment (SEQ ID NOS: 5, 7, 9, 11, 11, 7 or 23) may be used under stringent conditions.
- the gene of the present invention also includes a DNA that can be hybridized below and that encodes a protein having an activity to bind to an extracellular matrix.
- the stringent conditions include, for example, a salt (sodium) concentration of 150 to 900 mM, a temperature of 55 to 75 ° C, preferably a salt (sodium) concentration of 150 to 200 mM, and a temperature of 60 to 70 °.
- a salt (sodium) concentration of 150 to 900 mM a temperature of 55 to 75 ° C, preferably a salt (sodium) concentration of 150 to 200 mM, and a temperature of 60 to 70 °.
- a DNA having a nucleotide sequence complementary to a DNA encoding the Del-I partial fragment (shown in SEQ ID NO: 13) and a DNA capable of hybridizing under stringent conditions are used.
- the DNA of the present invention also includes a DNA encoding a protein having an activity of suppressing deposition on the extracellular matrix.
- extracellular matrix ECM is an extracellular biological structure in animal tissue, and refers to an aggregate of biopolymers that are synthesized inside the cell and secreted and accumulated outside the cell. You.
- the main components are collagen, elastin, proteodalican, glycosaminodalican, and glycoprotein.
- the term “depositing activity” refers to an activity in which all or a part of Del-l binds to the extracellular matrix, for example, those having higher deposition activity than full-length Del-l, and those having higher deposition activity than full-length Del-l. Or less than full-length Del-l but with equivalent deposition activity.
- the activity to suppress the deposition on extracellular matrix refers to the activity of reducing the deposition activity and increasing the soluble fraction regardless of the presence of the central region CY and the positive regulatory region XC due to the presence of the negative regulatory region. means.
- the measurement of the deposition activity or the activity of suppressing the deposition on the extracellular matrix is performed, for example, as follows.
- a DNA encoding a marker such as alkaline phosphatase is ligated to the DNA of the present invention, and the resulting DNA is transferred to predetermined cells (eg, cos7 cells, CHO cells, NIH3T3 cells, etc.). Insert and culture. After removing the culture supernatant and cells from the culture vessel, the alkaline phosphatase substrate is added to the extracellular matrix remaining in the culture vessel to develop color, and the deposition activity is measured. Since the marker (alkaline phosphatase) is also bound to the Del-l partial fragment, when the Del-l partial fragment is deposited on the extracellular matrix, the binding activity can be measured using the marker as an indicator. As well as identify the binding position.
- predetermined cells eg, cos7 cells, CHO cells, NIH3T3 cells, etc.
- the substrate when a soluble alkaline phosphatase substrate is used, the substrate develops a color (for example, develops a yellow color, etc.), so that the deposition activity can be easily measured by measuring the absorbance at a specific wavelength. it can.
- the deposition site when a depositable alkaline phosphatase is used, the deposition site is colored (for example, purple), and thus the deposition site can be easily identified by microscopic observation or the like.
- the enzyme is not limited to alkaline phosphatase, and other GFPs and mutants thereof, tags such as myc and His, GST proteins, isotopes, and biotinylated proteins can be used. It is also possible to perform the assay using reporter genes such as chloramphenicyltransferase (CAT) gene, luciferase gene, and / 3 galactosidase.
- CAT chloramphenicyltransferase
- a recombinant vector containing the DNA of the present invention can be obtained by ligating (inserting) the DNA of the present invention into an appropriate vector.
- the vector for inserting the DNA of the present invention is not particularly limited as long as it can be replicated in a host, and examples thereof include plasmid DNA, phage DNA, and virus.
- Examples of the plasmid DNA include a plasmid derived from Escherichia coli, a plasmid derived from Bacillus subtilis, and a plasmid derived from yeast, and the phage DNA includes ⁇ phage.
- the vector of the present invention includes a promoter, the DNA of the present invention, cis elements such as enhancer, splicing signal, polyaddition signal, Selection markers, ribosome binding sequences (SD sequences), etc. can be linked.
- the selection marker include a dihydrofolate reductase gene, an ampicillin resistance gene, a neomycin resistance gene and the like.
- the transformant of the present invention can be obtained by introducing the recombinant vector of the present invention into a host so that the target gene can be expressed.
- the host is not particularly limited as long as it can express the DNA of the present invention.
- bacteria, yeast, animal cells, and insect cells well known in the field can be used.
- experimental animals such as mice, livestock such as pigs, and plants such as rice and corn can be used.
- the recombinant vector of the present invention is capable of autonomous replication in the bacterium and can contain a promoter, a ribosome binding sequence, the DNA of the present invention, and a transcription termination sequence.
- Bacteria include Escherichia coh, Bacillus subtilis, and the like.
- the promoter for example, trp promoter, lac promoter, PL promoter, PR promoter and the like are used.
- the method for introducing the recombinant vector into bacteria is not particularly limited, and examples thereof include a method using calcium ions and an electroporation method.
- yeast When yeast is used as a host, for example, Saccharomyces cerevisiae, Schizosaccharomyces pombe and the like are used.
- the promoter is not particularly limited as long as it can be expressed in yeast.
- examples include gall promoter, gallO promoter, heat shock protein promoter, MF al promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter and the like.
- Methods for introducing the recombinant vector into yeast include, for example, elect-portation method, spheroplast method, lithium acetate method and the like.
- monkey cells cos7 cells
- Vero Chinese hamster ovary cells
- mouse L cells mouse L cells
- rat GH3 cells or human FL, HEK293 cells and the like
- promoter include an SRa promoter, an SV40 promoter, an LTR promoter, a / 3-actin promoter, and the like.
- Methods for introducing the recombinant vector into animal cells include, for example, the elect-portion method, the calcium phosphate method, and the lipofection method.
- Sf9 cells When insect cells are used as a host, Sf9 cells, Sf21 cells, and the like are used.
- a method for introducing the recombinant vector into insect cells for example, a calcium phosphate method, a ribofection method, an electoral poration method, or the like is used.
- transgenic animals For gene transfer into animals and plants, there are a method using a viral vector and a lipofection method. It is also possible to produce transgenic animals by introducing genes into germ cells and ES cells.
- the Del-1 partial fragment of the present invention can be obtained by culturing or breeding the transformant and collecting it from the culture or breeding product.
- culture refers to any of a culture supernatant, a cultured cell, a cultured cell, or a cell or cell fragment.
- Culture refers to any animal, plant body, tissue, secretion, excrement, or processed product thereof.
- the method for culturing the transformant of the present invention is performed according to a usual method used for culturing a host.
- a medium for culturing a transformant using a bacterium, a yeast, or the like as a host contains a carbon source, a nitrogen source, inorganic salts, and the like that can be utilized by the microorganism, and can efficiently perform culturing of the transformant. If so, either a natural medium or a synthetic medium may be used.
- carbohydrates such as glucose, fructose, sucrose and starch, organic acids such as acetic acid and propionic acid, and alcohols such as ethanol and propanol are used.
- ammonia, ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, etc., eptone, meat extract, corn steep liquor and the like are used.
- inorganic substance potassium phosphate monobasic, potassium phosphate dibasic, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like are used.
- the cultivation is usually performed under aerobic conditions such as shaking cultivation or aeration and stirring cultivation, for example, at 37 ° C. for 12 to 24 hours. Adjustment of the pH is performed using an inorganic or organic acid, an alkaline solution or the like.
- an inducer may be added to the medium as necessary.
- IPTG isopropyl- ⁇ -D-thiogalactoside
- a medium for culturing a transformant obtained using animal cells as a host commonly used RPMI-1640 medium, DMEM medium, or a medium obtained by adding fetal calf serum or the like to such a medium is used.
- Culturing is usually, 5% C0 2 presence is performed 1-4 days at 37 ° C.
- antibiotics such as kinamicin and benicillin may be added to the medium as needed.
- the proteins are extracted by disrupting the cells or cells.
- the culture solution may be used as it is, or the cells or cells may be removed by centrifugation or the like. Then, by using general biochemical methods used for protein isolation and purification, such as ammonium sulfate precipitation, gel chromatography, ion exchange chromatography, affinity chromatography, etc., alone or in combination as appropriate.
- the Del-II partial fragment of the present invention can be isolated and purified from the culture.
- the leaves, flowers, fruits, roots, etc., as well as the soil and water used for cultivation can be used for general biochemical methods such as ammonium sulfate precipitation, gel chromatography, ion exchange chromatography.
- the Del-l partial fragment of the present invention can be isolated and purified by using chromatography, affinity chromatography or the like alone or in an appropriate combination.
- synthesis of a partial Del-1 fragment by in vitro translation can be employed.
- two methods a method for converting RNA into type III and a method for converting DNA into type II (transcription Z translation)
- type I DNA include those having a promoter and a liposome binding site upstream of the translation initiation site; DNA, and DNA incorporating a promoter required for transcription upstream of the translation initiation site.
- an in vitro translation system a commercially available system such as an Expressway TM system (Invitrogen), a TNT system (registered trademark; Promega), or the like can be used.
- the desired fragment can be isolated and purified by using the above biochemical methods alone or in an appropriate combination.
- a cell line or animal or plant that expresses the Del-l partial fragment and the target molecule can express the target gene and express the target gene (eg, protein, antibody, peptide, natural or synthetic compound, or other cells). , Or soluble molecules).
- the Del-1 partial fragment can also be used directly.
- a fusion protein in which the target molecule and the Del-1 partial fragment are bound is prepared. That is, the DNA encoding the molecule and the DNA encoding the Del-1 partial fragment are ligated and ligated to an appropriate vector. This is introduced into a host cell and cultured to produce a fusion protein in which the target molecule is linked. Ligation to a vector, introduction into a cell, a method for culturing a transformed cell, and a method for rearing and cultivating a transformant are the same as those described in the above sections 2 and 3.
- the Del-l partial fragment can be obtained by using an enzyme such as alkaline phosphatase or horseradish oxidase, or a reagent such as a fluorescent label containing fluorescein isothiocyanate (FITC), phycocyanin or rhodamine. Can be used for labeling.
- an enzyme such as alkaline phosphatase or horseradish oxidase
- a reagent such as a fluorescent label containing fluorescein isothiocyanate (FITC), phycocyanin or rhodamine.
- FITC fluorescein isothiocyanate
- rhodamine a fluorescent label containing fluorescein isothiocyanate
- the Del-1 partial fragment of the present invention since the Del-1 partial fragment of the present invention has an activity of depositing on an extracellular matrix, it can be used for a binding assay, affinity chromatography, immunoprecipitation, Western blotting, and the like.
- Identification of an expression target polypeptide that can bind to the Del-1 partial fragment can also be performed by screening a peptide library using the recombinant Del-1 partial fragment.
- the labeled fusion protein is incubated with the random peptide library and the Del-l partial fragment is allowed to bind to the peptides in the library.
- the library is then washed to remove unbound polypeptide.
- Alkaline phosphatase or peroxidase substrate such as 5-bromo-4-chloro-3-indolyl phosphate (BCIP), 3,3'-diaminobenzidine (DAB)
- BCIP 5-bromo-4-chloro-3-indolyl phosphate
- DAB 3,3'-diaminobenzidine
- the transformant is an animal or plant
- the fusion protein when expressed at a specific site, the Del-l partial fragment of the present invention is deposited on the extracellular matrix. It is concentrated. Therefore, the target molecule can be efficiently recovered and used by directly eating or biochemically extracting the agricultural and livestock products.
- the Del-1 partial fragment of the present invention has a deposition activity on an extracellular matrix.
- the Del-1 partial fragment of the present invention allows the site of deposition on the extracellular matrix to be visually observed.
- the Del-1 partial fragment of the present invention can be used as a reagent for identifying the site of deposition on the extracellular matrix, and can be used together with a marker, a chromogenic substrate, an antibody against the marker 1, etc. It can be included in an identification kit.
- a fusion protein comprising a target molecule and the Del-1 partial fragment of the present invention is expressed in a specific tissue
- the target molecule is fixed at a predetermined site of the extracellular matrix and does not migrate to another site. As a result, it is concentrated at that site.
- the nucleotide sequence encoding the Del-l partial fragment of the present invention can be used to express the target molecule in a specific tissue by combining with a promoter sequence specific to an appropriate cell, tissue or organ, It can be used as a vector for restriction and concentration.
- staining with BCIP revealed that extracellular alkaline phosphatase activity was present in the extracellular matrix.
- Del-l protein has much stronger extracellular matrix deposition ability than full-length Del-l protein, and serve to anchor other proteins such as alkaline phosphatase to the extracellular matrix. It means there is. 7. Modification of Artificial Artifacts with Bioactive Substances
- the bioactive substance By culturing Escherichia coli and cells that produce a fusion protein of a certain bioactive substance and a partial fragment of Del-l on an artifact, the bioactive substance can be deposited on the artifact without impairing its biological function.
- the results in Figure 2 show that the culture dish This indicates that it has been modified with an active substance called phosphasease. It can be applied to the modification of hemodialysis membranes and artificial materials for implantation.
- the Del-1 partial fragment of the present invention can deposit the target molecule on the extracellular matrix by binding the target molecule.
- the Del-l partial fragment of the present invention can artificially regulate the deposition activity by using a positive regulatory region and a negative regulatory region.
- the degree of deposition activity can be changed by the presence or absence of the YB region or XC region shown in FIG. 1, or by appropriately changing the length of these regions (4-8, 4 in FIG. 1). -13, 4-1 and XY).
- the fusion protein of the present invention can be used as a drug delivery system (drug delivery system: DDS).
- a gene encoding a fusion protein of 4-1 containing a central region and a positive regulatory region and an enzyme that converts a precursor of an anticancer drug into an anticancer drug is introduced into a cancer tissue. Thereafter, when a large amount of the precursor of the anticancer drug is administered, a high drug concentration can be obtained in the cancer tissue with respect to the healthy tissue.
- a CB (SEQ ID NO: 13 or 14) gene containing a negative regulatory region after treatment the previously introduced gene product is released into the blood and can be removed by hemodialysis etc. .
- Example ⁇ following more detailed description of the present invention through examples. However, the present invention is not limited to these embodiments.
- the base sequence of the primer is as follows.
- Reaction liquid composition (50 in 1):
- Del-1 partial fragment CB, CY, YB, XY, XC, human ⁇ , ⁇ only
- Del'l partial fragment FB (not shown in FIG. 1) Nos. 1576-2058), 4-15 (SEQ ID NO: 8) and CE (SEQ ID NO: 16) were prepared.
- Example 1 (1) Among the partial fragments prepared in Example 1, 4-8, 4- 13, 4- 14, 4- 1, 4 ⁇ 11, 2-6, Del-1 minor, 1-1, 2.3 were ligated to plasmid pAPtag-5 (Funakoshi) and introduced into cos7 cells. Three days after the introduction, the culture supernatant, cells and extracellular matrix were collected. First, after collecting the supernatant, the cells are detached from the bottom of the culture dish and incubated by adding PBS containing 0.05% EDTA and incubating, and the extracellular matrix is left at the bottom of the culture dish. Thus, the alkaline phosphatase activity contained in each was detected.
- plasmid pAPtag-5 Frakoshi
- alkaline phosphatase was expressed in the same manner as above by expressing CB (No. 1270-2058 of the nucleotide sequence shown in SEQ ID NO: 1), CY, YB, XY, XC, human XY and AP only. Activity was measured.
- XY and human XY showed higher alkaline phosphatase activity than wild-type full-length Del-1, and CB and CY did not have higher alkaline phosphatase activity than wild-type full-length Del-1, but had some alkalinity. Phosphatase activity was observed. In contrast, XC and YB did not show any activity of phospholipase.
- the active center region was CY shown in SEQ ID NO: 3 (regions 1270 to 1662 of the nucleotide sequence shown in SEQ ID NO: 1), and that the amino acid sequence of amino acids 218 to 348 in the amino acid sequence shown in SEQ ID NO: 2 was considered an area.
- XY in which XC is linked to CY has about 10 times the deposition activity as compared to the active center region CY alone.
- XC alone has almost no deposition activity. Therefore, XC was considered to be a positive regulatory region of extracellular matrix deposition activity, which enhances extracellular matrix deposition activity.
- CB in which YB is linked to CY has a deposition activity reduced by about 0.5 times as compared with the active center region CY alone. Therefore, YB was considered to be a negative regulatory region for the deposition activity on extracellular matrix, which reduces the deposition activity on extracellular matrix.
- Del-l minor the nucleotide sequence Nos. 619 to 1271 of SEQ ID NO: 1 or 4-1 was replaced with plasmid pAPtag-5 (Funakoshi) And introduced into cos7 cells. Three days after the introduction, the culture supernatant, cells and extracellular matrix were collected.
- a to D are the results of the samples prepared using Del-l minor
- E to H are the results of the samples prepared using 4-1.
- a and E show cells stained with a depositing alkaline phosphatase substrate (BCIP).
- B and F are the results of staining cells with BCIP after detaching the cells using 0.05% EDTA.
- C and G show the results when the cells were detached using 0.05% EDTA, and the remaining extracellular matrix was colored with soluble alkaline phosphatase substrate (PNPP).
- D and H are the results obtained when PNPP was added to the cell culture solution (culture supernatant) and the color reaction was performed, as was conventionally performed.
- the site stained purple is the active site of alkaline phosphatase, ie, the deposition site of 4-1 (E). From the results in FIGS. 2E and F, it can be seen that 4-1 was deposited on cells and extracellular matrix. In contrast, Del-l minor did not deposit on either cells or extracellular matrix (A, B).
- the extracellular group can be directly used using an absorbance meter or the like. Allelic phosphatase activity in the substance can be measured.
- alkaline phosphatase activity in the extracellular matrix and in the culture supernatant was measured for the Del-l partial fragment (4-1) and the full-length Del-l, and the two were compared. -1) had 2.5 times higher deposition activity on the substrate than full-length Del-l.
- the beta-galactosidase gene was introduced simultaneously with the AP / XY or AP, and the beta-galactosidase activity was measured together with the alkaline phosphatase activity. Then, the measured value (AP / Lac ratio) was obtained by dividing the measured overnight galactosidase activity by the value of beta-galactosidase activity. In addition, when the AP / Lac ratio of the plasma or liver tissue collected from the liver of a mouse into which only the alkaline phosphatase gene (AP) was introduced was set to “1”, XY and the alkaline phosphatase gene were compared.
- the graph shows the AP / Lac ratio in plasma or liver tissue collected from the liver of a mouse transfected with DNA (AP / XY) to which the DNA was ligated.
- FIG. 3 shows the AP / Lac ratio in plasma collected from each liver
- FIG. 4 shows the AP / Lac ratio in liver tissue collected from each liver.
- the liver tissue collected from the liver into which AP / XY had been introduced had an AP / Lac ratio approximately 8 times that of the liver tissue collected from the liver into which only AP had been introduced. ( Figure 4).
- the AP / Lac ratio in plasma the AP / Lac ratio was almost 0 in plasma collected from the liver into which AP / XY had been introduced, since almost no AP activity was detected.
- liver tissue prepared from the liver of the mouse transfected with AP / XY prepared in (3) (B, E, F). Similarly, the liver tissue of a mouse transfected with only AP (A, C, D) D
- FIG. 5 is a diagram showing staining with Ari lipophosphatase staining (A, B, C, E) and / 3 galactosidase (D, F) using a frozen section of liver tissue collected from each liver.
- a and B are observations at 40x magnification
- C, D, E and F are observations at 200x magnification. It can be seen that AP / XY (B) is clearly deposited with respect to AP (A).
- C, D and E, F are serial sections, respectively, stained with both alkaline phosphatase and j3 galactosidase.
- cos7 cells were cultured for 72 hours, and the culture medium (medium) and extracellular matrix (ECM) were collected and subjected to Western blot.
- Laminin and albumin were used as controls.
- FIG. 6 is a photograph showing electrophoresis by Western blotting.
- a photograph showing electrophoresis using laminin as a control is arranged in the upper row, and a photograph showing electrophoresis using albumin as a control is arranged in the lower row.
- This example shows an example in which the enzyme was recovered as an expression product of the target gene.
- the recovery of alkaline phosphatase was confirmed by performing detection by a color reaction with a substrate of alkaline phosphatase.
- Example 2 After culturing the cells for 3 days, the cells were removed with a 0.05% EDTA solution, and the extracellular matrix on the bottom was collected with a scraper. After centrifuging the collected sample and removing the supernatant after centrifugation to prepare a pellet, the same operation as in Example 2 (Fig. 3B, F) is performed to obtain a substrate for alkaline phosphatase. Color was developed by adding BCIP.
- Fig. 7 shows the results.
- (a) is a wild-type cos7 cell
- (b) is a cos7 cell into which only the alkaline phosphatase gene has been introduced
- (c) is a fusion gene obtained by connecting the 4-1 partial fragment and the alkaline phosphatase gene
- a target molecule can be efficiently deposited on an extracellular matrix or an artificial material, and the target molecule can be used for recovery or removal by the deposition.
- the target molecule can be deposited on the extracellular matrix using the Del-1 partial fragment, and the outflow into plasma can be highly prevented.
- the fusion protein having the partial fragment of Del-1 and the target molecule can be used as a drug delivery system with few side effects.
- the degree of local concentration and localization of the target molecule can be controlled to a high degree, and an extremely high-performance drug delivery system Can be used as
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511158A JP4817233B2 (ja) | 2003-06-30 | 2004-06-30 | 細胞外基質沈着タンパク質 |
US10/563,166 US7517655B2 (en) | 2003-06-30 | 2004-06-30 | Protein capable of deposition onto extracellular matrix |
EP04747085A EP1650302B1 (en) | 2003-06-30 | 2004-06-30 | Protein capable of deposition onto extracellular matrix |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003188598 | 2003-06-30 | ||
JP2003-188598 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005001093A1 true WO2005001093A1 (ja) | 2005-01-06 |
Family
ID=33549758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009616 WO2005001093A1 (ja) | 2003-06-30 | 2004-06-30 | 細胞外基質沈着タンパク質 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7517655B2 (ja) |
EP (1) | EP1650302B1 (ja) |
JP (1) | JP4817233B2 (ja) |
WO (1) | WO2005001093A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044794A1 (fr) | 2006-10-10 | 2008-04-17 | Nihon University | Réactif auxiliaire pour tranfert de gène |
WO2010053199A1 (ja) * | 2008-11-10 | 2010-05-14 | 学校法人日本大学 | 前立腺癌の治療用医薬組成物及び前立腺癌の治療方法 |
WO2011025050A1 (ja) | 2009-08-25 | 2011-03-03 | 学校法人日本大学 | アポトーシス誘導剤 |
WO2013118839A1 (ja) * | 2012-02-10 | 2013-08-15 | 独立行政法人国立循環器病研究センター | 酸化ldl阻害剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5791022B2 (ja) | 2010-12-13 | 2015-10-07 | 学校法人日本大学 | 細胞遊走調節剤 |
US20140302027A1 (en) * | 2011-09-26 | 2014-10-09 | University Of Louisville Research Foundation, Inc. | Methods of treating periodontal inflammation and periodontal bone loss |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507527A (ja) | 1995-06-07 | 1999-07-06 | プロジェニター,インコーポレーテッド | 発生的に調節される内皮細胞遺伝子座−1 |
WO2002036826A2 (en) * | 2000-11-06 | 2002-05-10 | Gene Logic, Inc. | Del-1 and benign prostatic hyperplasia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041801B1 (en) | 1995-06-07 | 2006-05-09 | Vanderbilt University | Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1 |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
-
2004
- 2004-06-30 WO PCT/JP2004/009616 patent/WO2005001093A1/ja active Application Filing
- 2004-06-30 JP JP2005511158A patent/JP4817233B2/ja not_active Expired - Fee Related
- 2004-06-30 US US10/563,166 patent/US7517655B2/en not_active Expired - Fee Related
- 2004-06-30 EP EP04747085A patent/EP1650302B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507527A (ja) | 1995-06-07 | 1999-07-06 | プロジェニター,インコーポレーテッド | 発生的に調節される内皮細胞遺伝子座−1 |
WO2002036826A2 (en) * | 2000-11-06 | 2002-05-10 | Gene Logic, Inc. | Del-1 and benign prostatic hyperplasia |
Non-Patent Citations (2)
Title |
---|
HIDAI, C. ET AL., GENES & DEVELOPMENT, vol. 12, 1998, pages 21 - 33 |
See also references of EP1650302A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044794A1 (fr) | 2006-10-10 | 2008-04-17 | Nihon University | Réactif auxiliaire pour tranfert de gène |
JPWO2008044794A1 (ja) * | 2006-10-10 | 2010-02-18 | 学校法人日本大学 | 遺伝子導入補助試薬 |
WO2010053199A1 (ja) * | 2008-11-10 | 2010-05-14 | 学校法人日本大学 | 前立腺癌の治療用医薬組成物及び前立腺癌の治療方法 |
WO2011025050A1 (ja) | 2009-08-25 | 2011-03-03 | 学校法人日本大学 | アポトーシス誘導剤 |
JP5786266B2 (ja) * | 2009-08-25 | 2015-09-30 | 学校法人日本大学 | アポトーシス誘導剤 |
WO2013118839A1 (ja) * | 2012-02-10 | 2013-08-15 | 独立行政法人国立循環器病研究センター | 酸化ldl阻害剤 |
JPWO2013118839A1 (ja) * | 2012-02-10 | 2015-05-11 | 独立行政法人国立循環器病研究センター | 酸化ldl阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1650302A4 (en) | 2006-08-30 |
US7517655B2 (en) | 2009-04-14 |
US20060199184A1 (en) | 2006-09-07 |
JP4817233B2 (ja) | 2011-11-16 |
EP1650302A1 (en) | 2006-04-26 |
JPWO2005001093A1 (ja) | 2007-09-27 |
EP1650302B1 (en) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2249617C2 (ru) | ТРАНСКРИПЦИОННАЯ РЕГУЛЯТОРНАЯ ДНК ГЕНА ХОМЯКА EF-1α | |
DE69630153T2 (de) | Diagnose der Tumorausbreitung | |
AU2001250912C1 (en) | VEGF-modulated genes and methods employing them | |
US6103466A (en) | Double-muscling in mammals | |
WO1992005267A1 (fr) | Procede pour introduire de l'adn etranger dans une cellule | |
JPH06503949A (ja) | 新規インシュリン様成長因子結合タンパク質igfbp―5 | |
WO1995035319A1 (en) | Ctcf | |
JP4817233B2 (ja) | 細胞外基質沈着タンパク質 | |
AU726918B2 (en) | TGFbeta signal transduction proteins, genes, and uses related thereto | |
DE69934415T2 (de) | Neuartiges collectin | |
WO1998008860A1 (en) | Novel polynucleotide sequences encoding proteins involved in myogenesis | |
WO1997022697A9 (en) | TGFβ SIGNAL TRANSDUCTION PROTEINS, GENES, AND USES RELATED THERETO | |
AU710551B2 (en) | Nucleic acid encoding a nervous tissue sodium channel | |
US6087485A (en) | Asthma related genes | |
KR20020026430A (ko) | PrP-유사 유전자 | |
Sørensen et al. | Alternative splicing, expression, and gene structure of the septin-like putative proto-oncogene Sint1 | |
WO1994005776A1 (en) | Myocyte-specific transcription enhancing factor 2 | |
CA2203613C (en) | Secreted .alpha.-amylase as a reporter gene | |
US5837535A (en) | Neuronal-neonatal gene: neuronatin | |
DE69823022T2 (de) | Neues, menschliches tumorsuppressorgen. | |
US20050064411A1 (en) | Novel gene nedl-1 | |
EA003694B1 (ru) | Полипептиды, содержащие домены протеина gax, участвующие в подавлении транскрипции и/или взаимодействующие с другими протеинами, соответствующие нуклеиновые кислоты и их применение | |
WO2000037617A1 (en) | Glutamine: fructose-6-phosphate aminotransferase ii enzyme and their encoding nucleic acids | |
DE69926415T2 (de) | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren | |
AU729130B2 (en) | Novel human tumour suppressor gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511158 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004747085 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10563166 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004747085 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10563166 Country of ref document: US |